Lipocine Inc. - Common Stock — 四半期キャッシュフロー (NASDAQ:LPCN) | MetaTrader

チャート全体を表示 Full chart

Financials

概要明細書統計

総資産 22.51 M20.5 M18.58 M16.07 M17.01 M25.36 M 負債合計 1.51 M1.3 M1.45 M1.93 M2.53 M2.53 M 純資産合計 21 M19.2 M17.13 M14.14 M14.48 M22.83 M 負債および純資産合計 22.51 M20.5 M18.58 M16.07 M17.01 M25.36 M 有利子負債合計 —————— 純負債 ——————

ニュース

Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.13%

Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?

Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates

Lipocine completes patient visits in phase 3 trial for PPD treatment

H.C.ワインライト、リポシン社の株価目標を臨床試験進捗により15ドルに引き上げ

H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress

Lipocine completes enrollment in phase 3 trial for PPD treatment

リポシン社のPPD薬臨床試験、安全性評価で継続決定

Lipocine’s PPD drug trial continues after positive safety review

リポシン、産後うつ薬の治験で80%の登録を達成